Telomir Pharmaceuticals Inc TELO
๐ Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-09 |
| Shares Out. | 68,770,000 |
| Website | telomirpharma.com/ โ |
| Phone | 17863966723 |
| Employees | 5 |
| Net Income | -$990,947 |
| Total Assets | $5.8M |
| Total Liabilities | $827,310 |
| Equity | $5.0M |
About Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Telomir Pharmaceuticals Inc is a publicly traded company under the ticker symbol TELO on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

